Expression of transmembrane 4 superfamily member, CD9, is related to improved progression-free survival in patients with diffuse non-Hodgkin's lymphoma.
JC Yau, LK Dabbagh, KS Formenti… - Oncology …, 1998 - spandidos-publications.com
JC Yau, LK Dabbagh, KS Formenti, RW Coupland, BF Burns, AR Shaw
Oncology reports, 1998•spandidos-publications.comDecreased expression of the transmembrane 4 superfamily member, CD9, is associated
with poor prognosis in patients with breast or non-small cell lung cancer. The expression of
CD9 in lymphoma was examined in this study. Fifty-one sections with diffuse lymphomas
were examined. Thirty-seven had low expression and 14 high expression of CD9. At 5 years
the progression-free survival rates were 83.3+/-10.8% and 32.8+/-9.2%(p= 0.018), and the
actual survival were 83.3+/-10.8% and 56.8+/-8.9%(p= 0.256) for those with high and low …
with poor prognosis in patients with breast or non-small cell lung cancer. The expression of
CD9 in lymphoma was examined in this study. Fifty-one sections with diffuse lymphomas
were examined. Thirty-seven had low expression and 14 high expression of CD9. At 5 years
the progression-free survival rates were 83.3+/-10.8% and 32.8+/-9.2%(p= 0.018), and the
actual survival were 83.3+/-10.8% and 56.8+/-8.9%(p= 0.256) for those with high and low …
Abstract
Decreased expression of the transmembrane 4 superfamily member, CD9, is associated with poor prognosis in patients with breast or non-small cell lung cancer. The expression of CD9 in lymphoma was examined in this study. Fifty-one sections with diffuse lymphomas were examined. Thirty-seven had low expression and 14 high expression of CD9. At 5 years the progression-free survival rates were 83.3+/-10.8% and 32.8+/-9.2%(p= 0.018), and the actual survival were 83.3+/-10.8% and 56.8+/-8.9%(p= 0.256) for those with high and low CD9 expression respectively. Decreased expression of CD9 appears to be a prognostic factor for poor survival in patients with diffuse lymphomas.
Spandidos Publications